Literature DB >> 11180747

Duchenne Muscular Dystrophy.

Susan T. Iannaccone1, Zohair Nanjiani.   

Abstract

Duchenne muscular dystrophy (DMD) is not treatable; there is no cure. More than a decade ago, randomized trials demonstrated that oral steroid therapy was of benefit to DMD patients by prolonging ambulation. Although few significant side effects were reported, study patients were followed for 18 months or less. However, when treating DMD with steroids, the clinician must consider beginning treatment in mid-childhood and continuing until adolescence or longer, a total of at least 10 years. There is no evidence that steroids are associated with prolonged life or with improved pulmonary or cardiac function in DMD. It is clear that the risk of side effects increases with duration of use of oral steroids. Therefore, oral steroids are not recommended for treatment of DMD on a routine basis. If, in certain cases, one does institute therapy, the patient should be monitored carefully for side effects, maintain dietary restriction, and exercise regularly.

Entities:  

Year:  2001        PMID: 11180747     DOI: 10.1007/s11940-001-0045-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  50 in total

1.  Verapamil in Duchenne muscular dystrophy.

Authors:  A E Emery; R Skinner; L C Howden; M B Matthews
Journal:  Lancet       Date:  1982-03-06       Impact factor: 79.321

2.  [Therapeutic trial with allopurinol in progressive muscular dystrophy (author's transl)].

Authors:  M Pineda; I Fábregues; J Campistol; E Fernández Alvarez; M Alvarez
Journal:  An Esp Pediatr       Date:  1982-01

3.  Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study.

Authors:  I M Siegel; J E Miller; R D Ray
Journal:  IMJ Ill Med J       Date:  1974-01

4.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.

Authors:  E R Barton-Davis; L Cordier; D I Shoturma; S E Leland; H L Sweeney
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.

Authors:  R C Griggs; R T Moxley; J R Mendell; G M Fenichel; M H Brooke; A Pestronk; J P Miller
Journal:  Arch Neurol       Date:  1991-04

6.  Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy.

Authors:  J M Florence; S Pandya; W M King; J D Robison; J Baty; J P Miller; J Schierbecker; L C Signore
Journal:  Phys Ther       Date:  1992-02

Review 7.  Gene therapy prospects for Duchenne muscular dystrophy.

Authors:  P R Clemens; C T Caskey
Journal:  Eur Neurol       Date:  1994       Impact factor: 1.710

8.  Effect of dantrolene in Duchenne muscular dystrophy.

Authors:  T E Bertorini; G M Palmieri; J Griffin; M Igarashi; A Hinton; J G Karas
Journal:  Muscle Nerve       Date:  1991-06       Impact factor: 3.217

9.  Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy.

Authors:  T E Bertorini; G M Palmieri; J W Griffin; M Igarashi; J McGee; R Brown; D F Nutting; A B Hinton; J G Karas
Journal:  Neurology       Date:  1988-04       Impact factor: 9.910

10.  Longitudinal study of spinal deformity in Duchenne muscular dystrophy.

Authors:  T Oda; N Shimizu; K Yonenobu; K Ono; T Nabeshima; S Kyoh
Journal:  J Pediatr Orthop       Date:  1993 Jul-Aug       Impact factor: 2.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.